Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome

University of Kansas

Status: Completed

Conditions: Prader-Willi Syndrome; Hyperphagia

Treatments: Device: tDCS

Study type: Interventional

Funder types: Other

Identifiers

NCT01863017

13155

Details and patient eligibility

About

The purpose of this study is to determine the effects of transcranial direct current stimulation (tDCS) as it modifies hyperphagia in obese subjects, non-obese subjects, and subjects with Prader-Willi syndrome (PWS).

Full description

PWS is characterized by hypotonia, feeding difficulties, developmental delay and failure to thrive during infancy, and by an insatiable appetite (hyperphagia), rapid weight gain and obesity in early childhood.

Hyperphagia is one of the most prominent and debilitating features of PWS, and currently no pharmaceutical drug has been successful in decreasing appetite in such patients.

tDCS is a safe, noninvasive method whereby a weak electric current is directly transmitted into the brain via external electrodes connected to a 9-volt radio battery. It is based on decades-old observations that nerve cell firing can be altered by low amplitude direct current (DC). The researchers in this study believe that tDCS may have a positive impact on hyperphagia and weight.

In this study, the investigators intend to assess whether the effects tDCS differ between obese subjects, non-obese subjects, and subjects with Prader-Willi syndrome by measuring the amplitude and latency of eyeblink startle responses to a set of food- and non-food-related visual stimuli in all subjects, various hyperphagia questionnaires, and cognitive and behavioral assessments. It is hypothesized that as a group, subjects with Prader-Willi syndrome will demonstrate behavioral and psychometric evidence of abnormal food image processing, craving and associated behaviors relative to our control groups, and this group may receive potentially beneficial effects from tDCS sessions. Obese subjects are also predicted to have decreased hyperphagia and food cravings as a result of tDCS.

Enrollment: 31 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy individuals and individuals diagnosed with Prader-Willi syndrome
• Provide informed consent to participate in the study
• Body Mass Index (BMI) <25kg/m2 (for non-obese subjects only)
• Body Mass Index (BMI) ≥30kg/m2 (for obese subjects only)

Exclusion criteria

• Subject is pregnant at time of enrollment in the study.

• Contraindications to tDCS:

  1. metal in the head
  2. implanted brain medical devices

• Clinically significant and unstable medical disorders (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure, pulmonary issues, or chronic obstructive pulmonary disease) as self-reported.

• Clinically significant and unstable psychiatric disorders (e.g., schizophrenia, schizoaffective disorder, other psychosis, bipolar illness, severe depression) as self-reported.

• Significant visual impairment, as self-reported

• History of auditory deficiencies, as self-reported

• History of alcohol or substance abuse within the last 6 months as self-reported

• Use of carbamazepine within the past 6 months as self-reported.

• Current use of antidepressants

• History of neurological disorders as self-reported

• History of neurosurgery as self-reported

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

31 participants in 2 patient groups

Sham tDCS

Sham Comparator group

Description:

Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.

Treatment:

Device: tDCS

Active tDCS

Experimental group

Description:

Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.

Treatment:

Device: tDCS